2015-11-16T13:04:38-06:00 2014-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2014-01-01 943384500 PATH DRUG SOLUTIONS INST 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2015-11-16 1 3019519090 2014 2016-02-25 16:41:14Z OLIVIA POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 5270106 0 X WWW.PATH.ORG X 2000 CA SEE PART III, LINE 1. 8 3 0 0 0 0 24735210 5259668 0 0 -11280 10438 95 0 24724025 5270106 5369107 6406305 0 0 0 0 0 0 0 3589631 4353184 8958738 10759489 15765287 -5489383 42859417 37978413 977931 1584692 41881486 36393721 X PATH DRUG SOLUTIONS (PDS) WORKS TO DEVELOP SAFE AND EFFECTIVE NEW MEDICINES FOR DISEASES THAT DISPROPORTIONATELY AFFECT PEOPLE IN LOW-RESOURCE SETTINGS AND ENSURE THAT THEY ARE AVAILABLE AND ACCESSIBLE WHERE THEY ARE NEEDED MOST. 0 0 9464948 5674296 PRODUCT DEVELOPMENT: ALTHOUGH MANY PEOPLE LIVING IN LOW-RESOURCE SETTINGS NEED NEW, MORE EFFECTIVE, AND LOWER-COST MEDICINES TO MEET CRITICAL HEALTH CHALLENGES (INCLUDING MALARIA, DIARRHEA, AND HIV), RESEARCH AND DEVELOPMENT FOR THESE DRUGS MAY NOT BE A PRIORITY FOR COMMERCIAL PHARMACEUTICAL GROUPS. PDS WORKS TO OVERCOME THIS BARRIER BY CREATING CROSS-SECTOR COLLABORATIONS, OPENING DOORS FOR THE SHARING AND DONATION OF INTELLECTUAL PROPERTY, AND HARNESSING THE SCIENTIFIC AND MANUFACTURING CAPACITY OF BOTH HIGH- AND LOW- OR MIDDLE-INCOME COUNTRIES. WE ASSEMBLE EXPERIENCED AND DEDICATED TEAMS; IDENTIFY PROMISING DRUG CANDIDATES; TRANSLATE THESE CANDIDATES INTO SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES; AND COLLABORATE WITH COMPANIES TO MANUFACTURE AND DISTRIBUTE NEWLY APPROVED THERAPIES TO THOSE WHO NEED THEM MOST.IN 2014, THE PDS TEAM, WORKING THROUGH CROSS-SECTOR PARTNERSHIPS, ADVANCED DRUG RESEARCH AND DEVELOPMENT TO COMBAT TOP THREATS TO WOMEN AND CHILDREN WORLDWIDE. THIS WORK BENEFITTED FROM THE EXPERTISE OF A NEW LEADER, DR. DAVID SHOULTZ, FORMERLY DIRECTOR OF GRANTEE AND PARTNER ENGAGEMENT AT THE BILL & MELINDA GATES FOUNDATION.IN A KEY MILESTONE IN PDS' FRONTLINE WORK TO STOP MALARIA, WE CELEBRATED THE DELIVERY OF THE FIRST LARGE-SCALE BATCHES OF ANTIMALARIAL TREATMENTS MADE WITH A NEW SEMISYNTHETIC ARTEMISININ DERIVATIVE. MORE THAN 1.7 MILLION TREATMENTS WERE SHIPPED TO BURUNDI, LIBERIA, NIGER, AND OTHER COUNTRIES IN AFRICA. THE SHIPMENTS MARKED A KEY MILESTONE FOR A GLOBAL PARTNERSHIP CONVENED BY PDS TO CREATE A STABLE, HIGH-QUALITY SOURCE OF THE KEY INGREDIENT IN GOLD-STANDARD MALARIA TREATMENTS. SEMISYNTHETIC ARTEMISININ COMPLEMENTS THE BOTANICAL SUPPLY OF ARTEMISININ, HELPING TO STRENGTHEN THE SUPPLY CHAIN, STABILIZE PRICING, AND ENSURE ACCESS TO TREATMENT FOR MILLIONS SICKENED BY MALARIA EVERY YEAR, MOST OF THEM YOUNG CHILDREN IN AFRICAN COUNTRIES. WITH GLOBAL PARTNERS, WE ALSO ADVANCED DEVELOPMENT OF A LONG-ACTING INJECTABLE FORMULATION OF RILPIVIRINE (TMC278) AS A PRE-EXPOSURE PROPHYLAXIS (PREP) TO PREVENT HIV INFECTION. PREP IS A STRATEGY THAT INVOLVES USE OF ANTIRETROVIRAL MEDICATIONS TO REDUCE THE RISK OF HIV INFECTION IN PEOPLE WHO ARE HIV NEGATIVE. RECENT CLINICAL TRIALS HAVE SHOWN THAT DAILY, ORAL PREP USING THE ANTIRETROVIRAL DRUGS TENOFOVIR AND EMTRICITABINE DRAMATICALLY REDUCES THE RISK OF HIV INFECTION FOR MEN AND WOMEN WHO TAKE IT AS DIRECTED. A LONG-ACTING FORMULATION OF PREP THAT REQUIRES LESS FREQUENT DOSING HAS THE POTENTIAL TO IMPROVE UPTAKE AND ADHERENCE OF HIV PREP. IT WOULD ALSO EXPAND THE GLOBAL TOOLBOX OF PREVENTION INTERVENTIONS, PROVIDING SAFE AND EFFECTIVE CHOICES TO ADDRESS DIFFERENT CIRCUMSTANCES AND PREFERENCES. IN 2014, THE TEAM PREPARED FOR A PHASE 2 STUDY TO TEST SAFETY AND ACCEPTABILITY OF LONG-ACTING INJECTABLE RILPIVIRINE AS PREP. 1052859 732009 INTERNATIONAL DEVELOPMENT: IN BANGLADESH AND NEPAL, PDS CONTINUED WORK TO ALIGN KEY STAKEHOLDERS TO SUPPORT ADOPTION OF COMBINATION THERAPIES WITH PAROMOMYCIN INTRAMUSCULAR INJECTION TO TREAT VISCERAL LEISHMANIASIS (VL), A DEVASTATING PARASITIC DISEASE COMMON TO BOTH COUNTRIES. IN PARTICULAR, PDS WORKED TO SUPPORT NATIONAL VL ELIMINATION EFFORTS AND FORTIFY PHARMACOVIGILANCE PROGRAMS FOR VL DRUGS IN BOTH COUNTRIES. AS PART OF THIS EFFORT, IN 2014 PDS DEPLOYED PASSIVE PHARMACOVIGILANCE PROCEDURES IN BANGLADESH AND NEPAL TO ENABLE TARGETED, SPONTANEOUS REPORTING OF ADVERSE REACTIONS TO DRUGS FOR VL TO THE WORLD HEALTH ORGANIZATION DATABASE. IN ADDITION, PDS PROVIDED PHARMACOVIGILANCE TRAINING TO APPROXIMATELY 358 HEALTH CARE PROVIDERS FROM 103 HEALTH CARE CENTERS IN THESE TWO COUNTRIES. OTHER WORK INCLUDED A CAPACITY-BUILDING PROGRAM FOR CLINICAL RESEARCHERS AND ETHICS COMMITTEES BASED IN INDIA. THE PROGRAM COLLABORATED WITH NATIONAL-LEVEL MEDICAL RESEARCH AND ACADEMIC INSTITUTIONS TO BUILD SUSTAINABLE AND HIGH-QUALITY MENTORSHIP TO ENHANCE CLINICAL RESEARCH IN INDIA. THE PROGRAM HAS DEVELOPED THREE CLINICAL RESEARCH ADVANCEMENT TOWARDS EXCELLENCE (OR "CREATE") RESOURCE CENTERS. THESE CENTERS WILL GENERATE UP TO 25 "SMART" ETHICS COMMITTEES REPRESENTING ALL REGIONS OF THE COUNTRY AND HELP GET THEM READY FOR ACCREDITATION.THE PROGRAM HAS ALSO DEPLOYED STATE-OF-THE-ART SOFTWARE FOR BIOSTATISTICS, DATA MANAGEMENT, AND PHARMACOVIGILANCE, WHICH EMPOWER INVESTIGATORS AND ETHICS COMMITTEES TO COMPLY MORE EFFICIENTLY WITH REGULATORY EXPECTATIONS. IN DECEMBER 2014, PDS ALSO ADVANCED A POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL) FOLLOW-UP STUDY IN VL-TREATED PATIENTS IN BANGALDESH AND ORGANIZED THE FOURTH MEETING OF THE PKDL CONSORTIUM IN ISTANBUL, TURKEY. THE PURPOSE WAS TO DISCUSS AN EMERGING NEED TO IMPROVE PKDL SURVEILLANCE. BECAUSE THIS PARTICULAR FORM OF VL CONTRIBUTES TO OVERALL VL TRANSMISSION, EFFORTS TO ADDRESS IT ARE ESPECIALLY IMPORTANT. 10517807 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 IN 0 0 0 0 0 0 0 0 X 8 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 STEVEN B DAVIS PRESIDENT & CEO 1.00 39.00 X X 0 569984 43512 OLIVIA D POLIUS TREASURER & CFO 1.00 39.00 X X 0 255770 39644 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 250848 39180 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 378301 41432 YORGE FLORES DIRECTOR 1.00 39.00 X 0 234210 38125 KEITH CHIRGWIN DIRECTOR 2.00 0.00 X 0 0 0 KEN DUNCAN DIRECTOR 2.00 0.00 X 0 0 0 DAN HARTMAN DIRECTOR (BEGAN 12/19/14) 2.00 0.00 X 0 0 0 0 1689113 201893 0 0 1 0 0 798172 4461496 5259668 10438 10438 5270106 0 0 10438 6096342 6096342 309963 309963 13081 13081 1400 1400 208188 197859 10329 1744 1744 40759 30451 10308 9366 9366 2012246 2012246 208034 208034 320825 320825 38299 37909 390 6614 6614 1686 1686 SUBCONTRACTS 1338135 1338135 EQUIPMENT R&M / PROC. 91233 89759 1474 SPONSORSHIPS 29000 29000 CURRENCY FLUCTUATION 24752 24752 7822 6375 1447 10759489 10517807 241682 0 763123 51703 28480673 25840796 13545716 12038366 701 707 35758 21081 111713 89857 31160 21856 2286 3904 42859417 37978413 977931 1584692 977931 1584692 X 1065513 624363 40815973 35769358 41881486 36393721 42859417 37978413 -5489383 1618 0 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 10759489 0 1 10759489 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 PART IV, SECTION A, LINE 6: PATH DRUG SOLUTIONS PROVIDED VARIOUS GRANTS DETAILED IN SCHEDULES F AND I. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8586 4707 3879 103127 85150 17977 21856 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 202890 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 2441919 EUROPE 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 30118 SOUTH ASIA 0 0 GRANTMAKING 309963 SOUTH ASIA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 152412 SOUTH ASIA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 51623 SOUTH ASIA 0 0 MANAGEMENT & GENERAL PRODUCT DEVELOPMENT 4569 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 1264 0 0 0 0 0 0 3194758 0 3194758 SOUTH ASIA INTERNATIONAL DEVELOPMENT 70624 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 81575 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 118443 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 39321 CHECK/WIRE 3 0 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 ST LOUIS UNIVERSITY 3700 WEST PINE MALL SUITE 357 ST LOUIS MO 63108 430654872 501(C)(3) 816169 PRODUCT DEVELOPMENT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 160599 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 5119574 GENERAL SUPPORT 3 0 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 STEVEN B DAVIS PRESIDENT & CEO 0 421692 0 147592 0 700 0 31000 0 12512 0 613496 0 0 OLIVIA D POLIUS TREASURER & CFO 0 255000 0 0 0 770 0 30281 0 9363 0 295414 0 0 DANIEL LASTER SECRETARY 0 250008 0 0 0 840 0 26668 0 12512 0 290028 0 0 DAVID C KASLOW DIRECTOR 0 377000 0 0 0 1301 0 28920 0 12512 0 419733 0 0 YORGE FLORES DIRECTOR 0 234210 0 0 0 0 0 28105 0 10020 0 272335 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING METHODS TO ESTABLISH COMPENSATION: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE FINAL 990 WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CFO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PDS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PDS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PDS DOES NOT HAVE EMPLOYEES. PDS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF IRC SECTION 509(A)(3), AND PDS CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF ABOVE A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PDS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PDS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 11A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ N/A N/A PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0